Category Archives: MS Treatment

Media Release 19th September 2013 One Dose, One Time Early Stage Breast Cancer Treatment Comes to New Zealand A team of Auckland breast cancer specialists is bringing an innovative one dose, one time treatment for women with certain types of early-stage breast cancer to New Zealand. Focus Radiotherapy, a New Zealand clinician-owned specialist radiation therapy service is introducing the new treatment option using the Zeiss Intrabeam intraoperative radiotherapy (IORT) system to the Southern Cross Hospital, North Harbour Auckland and intends to make it available to women across the country. The new treatment means a reduction in radiation treatment time for the patient; minimised exposure to healthy tissue and organs, such as the ribs, lungs, heart and opposite breast; no treatment delay for patients who must also undergo chemotherapy as part of their breast cancer treatment; and same day treatment with no hospitalisation required. One of the founders of Focus Radiotherapy, Auckland Breast Surgeon Dr Erica Whineray Kelly says: `This may be an excellent therapy option for women having breast-conserving surgery, also known as a lumpectomy. We are the first and only centre in New Zealand offering this revolutionary treatment. The Intrabeam system is used to deliver a prescribed dose of … Continue reading →

Most researchers have suspected MS is a disease of the brains white matter. A new study suggests the debilitating disorder originates in gray matter, and raises hopes for faster diagnoses By Julianne Chiaet MRI Scan of Brain Image: Flickr/Reigh LeBlanc Showcasing more than fifty of the most provocative, original, and significant online essays from 2011, The Best Science Writing Online 2012 will change the way... Read More It has taken a century so far for scientists to not figure out the cause of multiple sclerosis (MS). The inflammatory disease, which affects more than 2.1 million people worldwide, has been blamed on toxins, viruses and even food. Most recently, scientists have placed their bets on two major ideas: The first (and far more popular) hypothesis suggests MS begins in white matter, which influences how parts of the brain work together. White matter consists of bundles of axons covered in myelin, a white insulating fatty layer. In people with MS myelin degrades and nerve fibers are left exposed, causing problems in motor coordination and loss of senses. The second hypothesis suggests that MS begins in the gray matter, which affects thinking and learning. The white matter hypothesis overshadows its alternative in part … Continue reading →

A team of Auckland breast cancer specialists is bringing an innovative one dose, one time treatment for women with certain types of early-stage breast cancer to New Zealand. Focus Radiotherapy, a New Zealand clinician-owned specialist radiation therapy service is introducing the new treatment option using the Zeiss Intrabeam intraoperative radiotherapy (IORT) system to the Southern Cross Hospital, North Harbour Auckland and intends to make it available to women across the country. The new treatment means a reduction in radiation treatment time for the patient; minimised exposure to healthy tissue and organs, such as the ribs, lungs, heart and opposite breast; no treatment delay for patients who must also undergo chemotherapy as part of their breast cancer treatment; and same day treatment with no hospitalisation required. One of the founders of Focus Radiotherapy, Auckland Breast Surgeon Dr Erica Whineray Kelly says: This may be an excellent therapy option for women having breast-conserving surgery, also known as a lumpectomy. We are the first and only centre in New Zealand offering this revolutionary treatment. The Intrabeam system is used to deliver a prescribed dose of radiation during breast conserving surgery. The goal of this approach is to destroy remaining cancer cells, helping to … Continue reading →

By Robert Weisman / Globe Staff/ September 17, 2013 European regulators Tuesday put their stamp of approval on Genzymes multiple sclerosis drug candidate Lemtrada, giving the Cambridge biotechnology company its second MS treatment on the market in the European Union only weeks after it was first approved there. The move vindicated French drug maker Sanofi SAs decision to pay $20.1 billion for Genzyme in 2011, a deal that hinged on the potential of Lemtrada, then an experimental therapy. While it has not yet been approved for sale in the United States the Food and Drug Administration is expected to rule on Genzymes application by the end of the year Lemtrada won the European Commissions blessing both for patients who have taken other MS drugs as well as newly diagnosed patients. Full story for BostonGlobe.com subscribers. Copyright 2013 Globe Newspaper Company. Get the full story with unlimited access to BostonGlobe.com. Just 99 for 4 weeks. Get Access Now View original post here: Genzyme wins regulatory approval in Europe of its second drug to treat multiple sclerosis … Continue reading →

By RTT News, September 17, 2013, 01:20:00 AM EDT (RTTNews.com) - Genzyme, a Sanofi company (SNYNF, SNY) reported that the European Commission has granted marketing authorization for its multiple sclerosis treatment, Lemtrada, following the August 30th approval of Aubagio. Both the products are being planned to launch in the EU soon. Lemtrada is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis or RRMS with active disease defined by clinical or imaging features. Lemtrada 12 mg has a novel dosing and administration schedule of two annual treatment courses. The first treatment course of Lemtrada is administered through intravenous infusion on five consecutive days, while the second course is administered on three consecutive days, a year later. The Lemtrada clinical development program included two pivotal randomized Phase III trials comparing treatment with Lemtrada to high-dose subcutaneous interferon beta-1a in patients with RRMS who had active disease and were either new to treatment (CARE-MS I) or who had relapsed while on prior therapy (CARE-MS II), as well as an ongoing extension study. According to the company, in CARE-MS I, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates; the difference observed in slowing disability progression … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY) announced today that the European Commission has granted marketing authorization for Lemtrada. This follows the August 30th approval of Aubagio. The company intends to begin launching both products in the EU soon. The approvals of Lemtrada and Aubagio in the European Union represent an important milestone for Genzyme and demonstrate our focus on scientific innovation and commitment to multiple sclerosis patients, said Genzyme CEO and President, David Meeker, M.D. This is particularly exciting as the EU approval is the first for Lemtrada globally. We look forward to making these unique therapies available to MS patients very soon. Lemtrada is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features. Lemtrada 12 mg has a novel dosing and administration schedule of two annual treatment courses. The first treatment course of Lemtrada is administered via intravenous infusion on five consecutive days, and the second course is administered on three consecutive days, 12 months later. The Lemtrada clinical development program included two pivotal randomized Phase III studies comparing treatment with Lemtrada to high-dose subcutaneous interferon beta-1a (Rebif) in patients with RRMS … Continue reading →

Genzyme, now a Cambridge-based unit of the French drug giant Sanofi, said that regulators have given it approval to market a multiple sclerosis drug in the European Union. The drug is called Lemtrada, and it is one that Genzyme has high hopes for. Genzyme has a heritage in developing drugs for rare diseases. Now it is also looking to be a presence in the MS space, which analysts have estimated to be a $13 billion market. Another Massachusetts company, Biogen Idec, is already a major player in MS drugs. In a press release, Genzyme said Lemtrada has been indicated for the treatment of adult patients with relapsing remitting multiple sclerosis. A few weeks ago, European regulators granted approval to Aubagio, another Genzyme MS drug. MS, a disease estimated to affect more than 2.1 million people globally, is said to require highly individualized treatment approaches. Genzyme said it intends to begin launching both products in the European Union soon. The approvals of Lemtrada and Aubagio in the European Union represent an important milestone for Genzyme and demonstrate our focus on scientific innovation and commitment to multiple sclerosis patients,Genzyme chief executive and president David Meeker, MD, said in a statement.This is particularly … Continue reading →

Home Mail News Sports Finance Weather Games Groups Answers Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo! News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo! Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? Nightline Fix … Continue reading →

NEW YORK, Sept. 16, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth http://www.reportlinker.com/p01623519/Multiple-Sclerosis-Therapeutics-to-2019---Treatment-Diversification-Increasing-Efficacy-and-Pipeline-Innovation-Combine-to-Drive-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Summary GBI Research, the leading business intelligence provider, has released its latest research, "Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth". Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. The market is led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period 20122019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs … Continue reading →

How a Relapsing Multiple Sclerosis Treatment Works A relapsing multiple sclerosis MS treatment to help you manage your condition? This video shows how.. http://tinyurl.com/CheckMyBP. By: Charlie Kim … Continue reading →